SV Konstantinides, G Meyer, C Becattini… - European heart …, 2020 - academic.oup.com
determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the …
SK Kakkos, M Gohel, N Baekgaard… - European Journal of …, 2021 - ejves.com
2.1. 1. Epidemiology and burden of the disease. The annual incidence of first episode of symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …
NS Key, AA Khorana, NM Kuderer, K Bohlke… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …
J Steffel, P Verhamme, TS Potpara… - European heart …, 2018 - academic.oup.com
The current manuscript is the second update of the original Practical Guide, published in 2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …
Venous thromboembolism (VTE) is a significant health problem in the general population but especially in cancer patients. In this review, we discuss the epidemiology and burden of …
Introduction It is unclear if direct oral anticoagulants (DOACs) are effective and safe alternatives to low-molecular-weight heparin (LMWHs) for the treatment of cancer …
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at an increased risk of developing VTE and are more likely to …
Venous thromboembolism, comprising both deep vein thrombosis and pulmonary embolism, is a chronic illness that affects nearly 10 million people every year worldwide. Strong …
G Agnelli, C Becattini, R Bauersachs… - Thrombosis and …, 2018 - thieme-connect.com
International and national guidelines recommend low-molecular-weight heparin for the treatment of venous thromboembolism (VTE) in patients with cancer. The aim of the …